Biomerica, Inc. announced that the United Arab Emirates (UAE) Ministry of Health and Prevention has approved its Fortel Kidney Test for home use. This important regulatory milestone expands access to accurate, easy-to-use diagnostic tools supporting early identification of kidney damage in high-risk populations. The Fortel Kidney Test is a rapid, 10-minute diagnostic test that detects low levels of albumin in urine, a critical early marker of kidney disease.
The test is particularly valuable for people living with diabetes and hypertension, two of the leading risk factors for chronic kidney disease (CKD), which are prevalent in the UAE. Diabetes affects approximately one in four UAE nationals, while overall hypertension prevalence is about 31%. Early detection provides an opportunity for timely medical intervention that can slow or prevent progression to kidney failure.
This approval strengthens Biomerica’s growing presence in the Middle East, following the regional success of its EZ Detect Colon Disease Test and other innovative diagnostic products. Through partnerships with leading distributors and healthcare providers, the Fortel Kidney (Microalbumin) Test is planned to be available in pharmacies, clinics, and hospitals throughout the UAE. This initiative aligns local efforts with the global urgency to curtail the CKD burden.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.